tbuckley/cabot-search huggingface dataset:
The impact of gut microbiome enterotypes on ulcerative colitis: identifying key bacterial species and revealing species co-occurrence networks using machine learning
Authors: Xuangao Wu, Ting Zhang, TianShun Zhang, Sunmin Park
Journal: Gut Microbes (2023)

Ulcerative colitis (UC) is a chronic inflammatory intestinal disease affecting the colon and rectum, with its pathogenesis attributed to genetic background, environmental factors, and gut microbes. This study aimed to investigate the role of enterotypes in UC by conducting a hierarchical analysis, determining differential bacteria using machine learning, and performing Species Co-occurrence Network (SCN) analysis. Fecal bacterial data were collected from UC patients, and a 16S rRNA metagenomic analysis was performed using the QIIME2 bioinformatics pipeline. Enterotype clustering was conducted at the family level, and deep neural network (DNN) classification models were trained for UC and healthy controls (HC) in each enterotype. Results from eleven 16S rRNA gut microbiome datasets revealed three enterotypes: Bacteroidaceae (ET-B), Lachnospiraceae (ET-L), and Clostridiaceae (ET-C).
Boosting the synergism between cancer ferroptosis and immunotherapy via targeted stimuli-responsive liposomes
Authors: Zhuoya Gao, Jiarong Zhang, Yingchao Hou, Jinjin Lu, Jing Liang, Yufeng Gao, Boqi Li, Shuai Gao, Yanjun Zhao, Min Gao, Jinghua Chen
Journal: Biomaterials (2023)
A programmable releasing versatile hydrogel platform boosts systemic immune responses via sculpting tumor immunogenicity and reversing tolerogenic dendritic cells
Authors: Wangxian Fu, Xinchao Li, Yingjie Li, Rui Luo, Chunqing Ou, Dongxue Huang, Xiuqi Liang, Yanjie You, Qinjie Wu, Changyang Gong
Journal: Biomaterials (2023)
FAM3C in Cancer-Associated Adipocytes Promotes Breast Cancer Cell Survival and Metastasis
Authors: Sahee Kim, Jiyoung Oh, Chanho Park, Min Kim, Woobeen Jo, Chu-Sook Kim, Sun Wook Cho, Jiyoung Park
Journal: Cancer Research (2023)

Abstract Adipose tissue within the tumor microenvironment (TME) plays a critical role in supporting breast cancer progression. In this study, we identified FAM3 metabolism-regulating signaling molecule C (FAM3C) produced by cancer-associated adipocytes (CAA) as a key regulator of tumor progression. FAM3C overexpression in cultured adipocytes significantly reduced cell death in both adipocytes and cocultured breast cancer cells while suppressing markers of fibrosis. Conversely, FAM3C depletion in CAAs resulted in adipocyte–mesenchymal transition (AMT) and increased fibrosis within the TME. Adipocyte FAM3C expression was driven by TGFβ signaling from breast cancer cells and was reduced upon treatment with a TGFβ-neutralizing antibody. FAM3C knockdown in CAAs early in tumorigenesis in a genetically engineered mouse model of breast cancer significantly inhibited primary and metastatic tumor growth. Circulating FAM3C levels were elevated in patients with metastatic breast cancer compared with those with nonmetastatic breast cancer. These results suggest that therapeutic inhibition of FAM3C expression levels in CAAs during early tumor development could be a promising approach in the treatment of patients with breast cancer. Significance: High FAM3C levels in cancer-associated adipocytes contribute to tumor-supportive niches and are tightly associated with metastatic growth, indicating that FAM3C inhibition could be beneficial for treating patients with breast cancer.
Diet Matters in Breast Cancer Prognosis: Clinical Trial Evidence and Questions
Authors: Anne McTiernan
Journal: Clinical Cancer Research (2023)

Summary Diet and weight matter in breast cancer prognosis. The DIANA-5 randomized controlled trial found no effect of a Mediterranean macrobiotic diet on 5-year breast cancer recurrence, but high adherence was associated with a 41% lower risk of recurrence versus controls. The effects of substantial weight loss on prognosis remain unknown. See related article by Berrino et al., p. 965
Low-Dose Antithymocyte Globulin: A Pragmatic Approach to Treating Stage 2 Type 1 Diabetes
Authors: Timothy P. Foster, Laura M. Jacobsen, Brittany Bruggeman, Chelsea Salmon, Jennifer Hosford, Angela Chen, Miriam Cintron, Clayton E. Mathews, Clive Wasserfall, Maigan A. Brusko, Todd M. Brusko, Mark A. Atkinson, Desmond A. Schatz, Michael J. Haller
Journal: Diabetes Care (2023)

OBJECTIVE Low-dose antithymocyte globulin (ATG) (2.5 mg/kg) preserves C-peptide and reduces HbA1c in new-onset stage 3 type 1 diabetes, yet efficacy in delaying progression from stage 2 to stage 3 has not been evaluated. RESEARCH DESIGN AND METHODS Children (n = 6) aged 5–14 years with stage 2 type 1 diabetes received off-label, low-dose ATG. HbA1c, C-peptide, continuous glucose monitoring, insulin requirements, and side effects were followed for 18–48 months. RESULTS Three subjects (50%) remained diabetes free after 1.5, 3, and 4 years of follow-up, while three developed stage 3 within 1–2 months after therapy. Eighteen months posttreatment, even disease progressors demonstrated near-normal HbA1c (5.1% [32 mmol/mol], 5.6% [38 mmol/mol], and 5.3% [34 mmol/mol]), time in range (93%, 88%, and 98%), low insulin requirements (0.17, 0.18, and 0.34 units/kg/day), and robust C-peptide 90 min after mixed meal (1.3 ng/dL, 2.3 ng/dL, and 1.4 ng/dL). CONCLUSIONS These observations support additional prospective studies evaluating ATG in stage 2 type 1 diabetes.
The epigenetic evolution of glioma is determined by the IDH1 mutation status and treatment regimen
Authors: Tathiane M. Malta, Thais S. Sabedot, Natalia S. Morosini, Indrani Datta, Luciano Garofano, Wies R. Vallentgoed, Frederick S. Varn, Kenneth Aldape, Fulvio D'Angelo, Spyridon Bakas, Jill S. Barnholtz-Sloan, Hui K. Gan, Mohammad Hasanain, Ann-Christin Hau, Kevin C. Johnson, Simona Cazacu, Ana C. deCarvalho, Mustafa Khasraw, Emre Kocakavuk, Mathilde C.M. Kouwenhoven, Simona Migliozzi, Simone P. Niclou, Johanna M. Niers, D. Ryan. Ormond, Sun Ha Paek, Guido Reifenberger, Peter A. Sillevis Smitt, Marion Smits, Lucy F. Stead, Martin J. van den Bent, Erwin G. Van Meir, Annemiek Walenkamp, Tobias Weiss, Michael Weller, Bart A. Westerman, Bauke Ylstra, Pieter Wesseling, Anna Lasorella, Pim J. French, Laila M. Poisson, The GLASS Consortium, Roel G.W. Verhaak, Antonio Iavarone, Houtan Noushmehr
Journal: Cancer Research (2023)

Abstract Tumor adaptation or selection is thought to underlie therapy resistance in glioma. To investigate longitudinal epigenetic evolution of gliomas in response to therapeutic pressure, we performed an epigenomic analysis of 132 matched initial and recurrent tumors from patients with IDH-wildtype (IDHwt) and IDH-mutant (IDHmut) glioma. IDHwt gliomas showed a stable epigenome over time with relatively low levels of global methylation. The epigenome of IDHmut gliomas showed initial high levels of genome-wide DNA methylation that was progressively reduced to levels similar to those of IDHwt tumors. Integration of epigenomics, gene expression, and functional genomics identified HOXD13 as a master regulator of IDHmut astrocytoma evolution. Furthermore, relapse of IDHmut tumors was accompanied by histological progression that was associated with survival, as validated in an independent cohort. Finally, the initial cell composition of the tumor microenvironment varied between IDHwt and IDHmut tumors and changed differentially following treatment, suggesting increased neo-angiogenesis and T-cell infiltration upon treatment of IDHmut gliomas. This study provides one of the largest cohorts of paired longitudinal glioma samples with epigenomic, transcriptomic, and genomic profiling and suggests that treatment of IDHmut glioma is associated with epigenomic evolution towards an IDHwt-like phenotype.
Midazolam for Pregeneral Anesthesia Sedation—Aiming for Better Satisfaction in Elderly Patients
Authors: Zhiyi Zuo
Journal: JAMA Surgery (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Association of <i>PIK3CA</i> Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer
Authors: Paola Zagami, Aranzazu Fernandez-Martinez, Naim U. Rashid, Katherine A. Hoadley, Patricia A. Spears, Giuseppe Curigliano, Charles M. Perou, Lisa A. Carey
Journal: JAMA Network Open (2023)

PIK3CA mutations may be associated with outcomes of patients with ERBB2/HER2-positive early breast cancer (EBC).
New Editorial Board Members—September 2023
Authors: Melina R. Kibbe
Journal: JAMA Surgery (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Limitations to Assessing Withdrawal of Care in Children
Authors: Eric A. Sribnick, Julie C. Leonard, Jeffrey R. Leonard
Journal: JAMA Surgery (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
How Do Policymakers Regulate AI <i>and</i> Accommodate Innovation in Research and Medicine?
Authors: Melissa Suran, Yulin Hswen
Journal: JAMA (2023)

In this Medical News article, JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, and Alondra Nelson, PhD, the Harold F. Linder Professor at the Institute for Advanced Study, discuss effective AI regulation frameworks to accommodate innovation.
Ruxolitinib for Refractory PL-12 Antisynthetase Syndrome–Associated Angioedema-Like Panniculitis With Clonal T-Cell Receptor Gene Rearrangement
Authors: Srona Sengupta, Brandon Law, Rachel Sennett, Jaroslaw J. Jedrych, Jemima Albayda, Jun K. Kang
Journal: JAMA Dermatology (2023)

This case report describes a woman in her 30s who presented with a 3-year history of anti–PL-12 antisynthetase syndrome characterized by interstitial lung disease, arthritis, and myositis and was diagnosed with antisynthetase syndrome–associated panniculitis.
Efficacy and Safety of PF-07038124 in Patients With Atopic Dermatitis and Plaque Psoriasis
Authors: Lawrence F. Eichenfield, Sanela Tarabar, Seth Forman, Alfonso García-Bello, Gang Feng, Gerald Fetterly, Ping Mahling, Elena Peeva, Michael S. Vincent, Deepa E. Chandra
Journal: JAMA Dermatology (2023)

Importance Atopic dermatitis (AD) and plaque psoriasis are inflammatory skin diseases with unmet need for effective topical treatments with few application site reactions. Objective To assess the efficacy and safety of the topical phosphodiesterase 4 inhibitor PF-07038124 in patients with AD and plaque psoriasis. Design, Setting, and Participants This phase 2a, randomized, double-blind clinical trial was conducted from December 21, 2020, to August 18, 2021, at 34 sites across 4 countries. Eligible patients (aged 18-70 years) had mild to moderate AD (covering 5%-20% body surface area) or plaque psoriasis (covering 5%-15% body surface area). Data were analyzed until December 15, 2021. Interventions Patients were randomized (1:1) to PF-07038124, 0.01%, topical ointment or vehicle once daily for 6 weeks. Main Outcomes and Measures The primary end point was the percent change from baseline (CFB) in the Eczema Area and Severity Index (EASI) total score among patients with AD and in the Psoriasis Area and Severity Index (PASI) score among patients with plaque psoriasis at week 6. Safety measures included treatment-emergent adverse events, including application site reactions. Results Overall, 104 patients were randomized (mean [SD] age, 43.0 [15.4] years; 55 [52.9%] women; 4 [3.8%] Asian, 13 [12.5%] Black, and 87 [83.7%] White), including 70 with AD (41 women [58.6%]; mean [SD] ages, 41.4 [16.6] years in the PF-07038124 group and 36.1 [13.9] years in the vehicle group) and 34 with plaque psoriasis (20 men [58.8%]; mean [SD] ages, 51.8 [12.3] years in the PF-07038124 group and 51.2 [10.8] years in the vehicle group). Baseline characteristics were generally balanced. At week 6, the PF-07038124 groups showed significantly greater improvements compared with vehicle groups in EASI (least-squares mean CFB, −74.9% vs −35.5%; difference, −39.4% [90% CI, −58.8% to −20.1%]; P &amp;amp;lt; .001) and PASI scores (CFB, −4.8 vs 0.1; difference, −4.9 [90% CI, −7.0 to −2.8]; P &amp;amp;lt; .001). The number of patients with treatment-emergent adverse events was comparable between treatment groups in patients with AD (PF-07038124, 9 [25.0%]; vehicle, 9 [26.5%]) and plaque psoriasis (PF-07038124, 3 [17.6%]; vehicle, 6 [35.3%]). There were no application site reactions with PF-07038124 treatment. Conclusions and Relevance Topical PF-07038124 was well tolerated and demonstrated superior efficacy compared with vehicle in patients with mild to moderate AD and plaque psoriasis. Trial Registration ClinicalTrials.gov Identifier: NCT04664153
Iodine Intake and Testosterone
Authors: Arcangelo Barbonetti, Chiara Castellini, Francesca Di Giulio, Federica Antolini, Daniele Tienforti, Mario Muselli, Marco Giorgio Baroni
Journal: JAMA Network Open (2023)

This cross-sectional study evaluates whether urinary iodine concentration is associated with testosterone among men who participated in the National Health and Nutrition Examination Survey.
Program Offering Free COVID-19 and Flu Services Expands Nationwide
Authors: Emily Harris
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Antimicrobial Resistance Is Rising in Ukraine and Neighboring Areas
Authors: Emily Harris
Journal: JAMA (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Repeated Measurement for Validity in Data About Surgeon Gender Differences—Reply
Authors: My Blohm, Gabriel Sandblom, Johanna Österberg
Journal: JAMA Surgery (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Meaningful Change Thresholds for the Psoriasis Symptoms and Signs Diary
Authors: Kim A. Papp, Kenneth Gordon, Bruce Strober, Joe Zhuo, Brandon Becker, Yichen Zhong, Jennifer L. Beaumont, Tan P. Pham, Renata Kisa, Andrew A. Napoli, Subhashis Banerjee, April W. Armstrong
Journal: JAMA Dermatology (2023)

Change from baseline score on the validated Psoriasis Symptoms and Signs Diary (PSSD) is a widely used, patient-reported end point in clinical trials for psoriasis. Meaningful score change thresholds anchored to patient-reported assessments have not been established in a clinical trial setting.
Innovation in Development of Dermatologic Drugs Approved by the US Food and Drug Administration Between 2012 and 2022
Authors: Samir Kamat, Benjamin Ungar, Aneesh Agarwal, Joy Wan, Joseph S. Ross, Ravi Gupta
Journal: JAMA Dermatology (2023)

This cross-sectional study characterizes the frequency and degree of innovation of new dermatologic drugs approved by the US Food and Drug Administration (FDA) from 2012 to 2022.
A Nationwide Network of Health AI Assurance Laboratories
Authors: Nigam H. Shah, John D. Halamka, Suchi Saria, Michael Pencina, Troy Tazbaz, Micky Tripathi, Alison Callahan, Hailey Hildahl, Brian Anderson
Journal: JAMA (2023)

Importance Given the importance of rigorous development and evaluation standards needed of artificial intelligence (AI) models used in health care, nationwide accepted procedures to provide assurance that the use of AI is fair, appropriate, valid, effective, and safe are urgently needed. Observations While there are several efforts to develop standards and best practices to evaluate AI, there is a gap between having such guidance and the application of such guidance to both existing and new AI models being developed. As of now, there is no publicly available, nationwide mechanism that enables objective evaluation and ongoing assessment of the consequences of using health AI models in clinical care settings. Conclusion and Relevance The need to create a public-private partnership to support a nationwide health AI assurance labs network is outlined here. In this network, community best practices could be applied for testing health AI models to produce reports on their performance that can be widely shared for managing the lifecycle of AI models over time and across populations and sites where these models are deployed.
Dual Antiplatelet Therapy De-Escalation in Stabilized Myocardial Infarction With High Ischemic Risk
Authors: Myunhee Lee, Sungwook Byun, Sungmin Lim, Eun Ho Choo, Kwan Yong Lee, Donggyu Moon, Ik Jun Choi, Byung-Hee Hwang, Chan Joon Kim, Mahn-Won Park, Yun Seok Choi, Hee-Yeol Kim, Ki-Dong Yoo, Doo-Soo Jeon, Hyeon Woo Yim, Kiyuk Chang, Myung Ho Jeong, Chul-Soo Park, Woo Seung Shin, Dong Bin Kim, Sang Shik Jung, Byung Ryeol Cho, Jin Shin Ko, Won Kim, Seung Ho Huh, Ki Sik Kim, Sang Hyeon Kim, Chang Hyeon Cho, Sang Ho Park, Myung Ho Yoon, Jong Sun Park, Kyung Min Park, Seoung Hwan Lee, Kyung Tae Chung, Joon Hyeong Do, Sang Wook Kim, Joo Yeol Baek, Byung Joo Shim, Ki Chul Sung, Ju Hyun Oh, Kwang Soo Cha, Young Hoon Cho, Jae Sik Jang, Jin Man Cho, Jang Hoon Lee
Journal: JAMA Cardiology (2023)

In patients with acute myocardial infarction (AMI) who have high ischemic risk, data on the efficacy and safety of the de-escalation strategy of switching from ticagrelor to clopidogrel are lacking.